medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2016, Number 3

<< Back Next >>

VacciMonitor 2016; 25 (3)

Evaluation of immunogenicity and protective homologous capacity of a tetravalent Leptospira vaccine candidate, for veterinary use, including serogroup Ballum

Cuba-Romero Y, Gainza-Santos N, Saltaren-Cobas A, Naranjo-Medina M

Language: Spanish
References: 20
Page: 68-76
PDF size: 124.13 Kb.


ABSTRACT

Immunogenicity is an important parameter for studies of immunogens. The humoral immune response against leptospirosis is vital for resistance to the infection; hence this paper is proposed to evaluate the immunogenicity and protective homologous capacity of a tetravalent candidate that includes serogroup Ballum in its formulation. The strain 245-12 classified as L. borgpetersenii serovar Ballum was used in this paper, isolated from a confirmed case of leptospirosis. Five (5) batches of a tetravalent vaccine preparation were formulated with this strain previously characterized from the point of view of its virulence, which also contains the strains Canicola, Icterohaemorrhagiae and Pomona contained in the Polyvalent-Leptospira vaccine for veterinary use. The immunogenicity of this preparation was assessed by micro agglutination and homologous protection capacity in Golden Syrian Hamster before the challenge with 100 LD50. Animals were immunized with two doses of vaccine (0.1 mL) with an interval of 15 days; the challenge was carried out 14 days after the immunization schedule was ended. The results were compared with those obtained with the Polyvalent-Leptospira vaccine. All the batches of the tetravalent preparation formulated complied satisfactorily with the quality controls. The batches formulated in this study showed a significant immunogenicity and homologous protection capacity against serogroup Ballum and they were able to eliminate the carrier state in the immunized animals. This paper, for the first time sets the bases for novel vaccine formulations, in animals, containing the serogroup Ballum.


REFERENCES

  1. Haake DA, Levett PN. Leptospirosis in humans. Curren Topics in Microbiology and Inmunology 2015;387:65-97.

  2. Cuba Y, Gainza N, Batista N, Saltaren A, Naranjo M. Caracterización de aislamientos clínicos de Leptospira para su uso en vacunas veterinarias. VacciMonitor 2016;25(1):5-11.

  3. Levett P. Leptospirosis. Clin Microbiol Rev 2001;14(2):296-326.

  4. Adler B, de la Peña M. Leptospira and Leptospirosis. Vet Microbiol 2009;2:4382-92.

  5. Cruz R. Programa Nacional de Prevención y Control de la Leptospirosis. Informe del Programa de Zoonosis, Resultados 2010. Ciudad de la Habana: MINSAP; 2010.

  6. Obregón AM, Fernández C, Rodríguez I, Rodríguez J, Zamora Y. Avances de laboratorio en el diagnóstico serológico y la investigación de la leptospirosis humana en Cuba. Rev Cub Med Trop 2007;59(1):11-4.

  7. Rodríguez I, Fernández C, Obregón A, Zamora Y, Rodríguez J, Rodríguez N, et al. Comportamiento epidemiológico de la leptospirosis en Cuba (2006-2008). En: Leptospirosis Habana 2009, 8-12 de Junio 2009. La Habana: Cuba; 2009:6-9.

  8. Fletcher W. Recent work on leptospirosis, tsutsugamushi disease and tropical typhus in the Federated Malay States. Trans Roy Soc Trop Med Hyg 1928;21:265-82.

  9. Faine S. Guidelines for the control of leptospirosis. Geneva: W.H.O; 1982.

  10. Montenegro S, Gayol M, Torres M. Aspectos Éticos de la investigación con animales. Rev. Med. Rosario 2011;77:69-74.

  11. Capó M. Bioética Animal: Desarrollo de un Concepto. Animales de Experimentación. La Revista Hispanoamericana 1999;5(2):30- 40.

  12. Castillo F. El ratón como animal de laboratorio. La Habana: Editorial Ciencias Médicas; 1985.

  13. Naiman BM, Blumerman S, Alt D, Bolin C, Brown R, Zuerner R, et al. Evaluation of Th1 immune response in naive and vaccinated animals following challenge with Leptospira borgpetersenii serovar hardjo: Involvement of WC1(+) γ δ and CD4 T cells. Infect Immun 2002;70(11):6147-57.

  14. Organización Mundial de la Salud. Leptospirosis humana: guía para el diagnóstico, vigilancia y control. Rio de Janeiro: Centro Panamericano de Fiebre Aftosa–VP/OPS/OMS; 2008.

  15. Naranjo M. Evaluación microbiológica e inmunológica de cepas de Leptospira. Vacuna contra la leptospirosis conteniendo el serovar Ballum. Saarbrücken: Editorial Académica Española; 2016.

  16. Martínez R, Pérez A, Baró M, Álvarez M, Menéndez J, Díaz M, et al. Evaluación de la efi cacia de una nueva vacuna contra la leptospirosis humana en grupos de riesgo. Rev Panam Salud Pública 2000;8(6):385-92.

  17. Babudieri B, Castelli M, Pisoni F. Comparative test with formolized and irradiated vaccines against leptospirosis. Bull Wld Hlth Org 1973;48:587-90.

  18. Barnett J, Barnett D, Bolin C, Summers T, Wagar E, Cheville N, et al. Expression and distribution of leptospiral outer membrane components during renal infection of hamsters. Infect Immun 1999;67:853-61.

  19. Krishnan L, Dicaire C, Patel G, Sprott G. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated and memory responses: comparison to conventional liposomes and alum. Infect Immun 2000;68:54-63.

  20. Silva E, Santo C, Athanazio D, Seyffert N, Seixas F, Cerqueira GM, et al. Characterization of virulent of Leptospira isolates in hamster model. Vaccine 2008;26:3892-6.




2020     |     www.medigraphic.com